News and features

Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.

If you’re a journalist and want to find out more, you can contact our media relations team.

Prostate cancer patient with doctor and wife
New tool could help target prostate cancer testing at men at greatest risk

09/12/22

Scientists have created a comprehensive tool for predicting an individual’s risk of developing prostate cancer, which they say will help ensure that those men at greatest risk will receive the appropriate testing while reducing unnecessary – and potentially invasive – testing for those at very low risk.
Breast cancer cell
New targeted drug shows benefit against breast cancer in first phase III trial

08/12/22

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial.
patient-and-clinician_547x351
Capivasertib – a huge success story for UK science

08/12/22

The latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Henry French gives an update
Portrait photograph of Professor Daniel Catovsky taken in 2017.
ICR remembers internationally renowned haematologist and researcher Professor Daniel Catovsky

07/12/22

Scientists and clinicians at The Institute of Cancer Research, London, and from around the world, have shared their condolences and celebrated the many achievements of Professor Daniel Catovsky, who died last week.
A composite image of the ICR and Apollo Therapeutics logos
ICR announces new strategic collaboration with Apollo Therapeutics to develop novel cancer drugs

28/11/22

The Institute of Cancer Research, London, and biopharmaceutical company Apollo Therapeutics have announced a new collaboration that will advance the development of new cancer drugs, combining the strengths and expertise of both organisations.
Using cryo-electron microscopy, researchers obtained a detailed map (shown in orange) of the chain-like tankyrase structure.
Discovery could lead to new drugs to block protein that fuels bowel cancer

23/11/22

Scientists have revealed the inner workings of a key protein involved in a wide range of cellular processes – potentially paving the way for better and less toxic cancer drugs.
The strategy's three pillars, World class cancer research, Inspiring tomorrow's leaders, Growing our impact for patients
Scientists plot ‘extinction’ of cancers by disrupting their ecosystems

22/11/22

World-leading cancer researchers announce plans to create a new generation of treatments that target the ecosystems supporting cancer. Their new strategy sees cancer genetics and evolution within complex ecosystems as keys to creating new targeted drugs and immunotherapies. They aim to double survival for people with advanced cancer within a decade by combining existing treatments and using smart dosing strategies
Pipettes and well plates
Blood tests may prevent relapse in breast cancer patients

18/11/22

An innovative trial to detect relapse in breast cancer patients with circulating tumour DNA (ctDNA) has opened at our partner hospital, The Royal Marsden NHS Foundation Trust. The TRAK-ER trial, led by researchers at The Royal Marsden and The Institute of Cancer Research, London, will establish a circulating tumour DNA (ctDNA) surveillance programme for over 1,000 patiets with ER positive breast cancer who are currently receiving hormone therapy to reduce their risk of cancer returning.
Dr Sandra Hanks (left) and Naomi Costelloe (right) of Curesponse
New personalised cancer medicine company moves in at The London Cancer Hub’s Innovation Gateway

17/11/22

Personalised cancer medicine start-up Curesponse has become the latest MedTech company to move in at the Innovation Gateway at The London Cancer Hub in Sutton, south London.
ICR Logo
Scientists uncover potential ‘electrical language’ of cancer cells

11/11/22

Breast cancer cells may be able to communicate with each other using electrical impulses, new research suggests.
Breast cancer cell spheroid blue and purple
ICR urges continued negotiation after NICE rejection of olaparib for early breast cancer

10/11/22

The Institute of Cancer Research, London, is urging NHS-England, NICE and pharmaceutical company AstraZeneca to continue discussions after the disappointing decision not to recommend targeted drug olaparib for women with early-stage, high-risk, inherited breast cancer.
ICR Logo
Advanced radiotherapy safely treats prostate cancer patients in a quarter of the time of current standard

09/11/22

An advanced radiotherapy technique can be used to safely treat prostate cancer patients in as little as one to two weeks, compared with the current standard, which takes one to two months.

Make a donation today

A monthly gift can help support our research over several years, so it has the maximum possible benefit for people with cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

With your generous support, we can continue making more discoveries, finding more cures, and saving more lives.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Our research centres & divisions

Through our close partnerships with The Royal Marsden and other key UK institutions, we're leading a wide breadth of cancer research across eight divisions and more than 25 research centres and strategic initiatives.